ストックスクリーナーアプリを入手
4.31
4.86%
-0.22
前日終値:
$4.53
開ける：
$4.5
24時間の取引高:
47,311
Relative Volume:
0.10
時価総額：
$5.03M
収益：
$1,000
当期純損益:
$-11.39M
株価収益率:
-0.1403
EPS:
-30.7182
ネットキャッシュフロー:
$-7.26M
1週間 パフォーマンス:
-5.69%
1か月 パフォーマンス:
-2.49%
6か月 パフォーマンス:
-43.77%
1年 パフォーマンス:
-85.87%
1日の値動き範囲:
$4.21
$4.83
1週間の範囲:
$4.21
$4.83
52週間の値動き範囲:
$3.1829
$71.50
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
名前
Ernexa Therapeutics Inc
セクター
電話
(617) 798-6700
住所
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
4.31 | 5.27M | 1,000 | -11.39M | -7.26M | -30.72 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ernexa Therapeutics Inc (ERNA) 最新ニュース
Ernexa (ERNA) Quarterly Results: Reported EPS Misses Expectations in the Current Update; Post-Report: The Share Price Adds 4.68% on the DayEBITDA Analysis - vinanet.vn
ERNA Stock Surged 60% Today – Here’s Why Retail Is Buzzing About Ernexa’s Ovarian Cancer Trial Results - Stocktwits
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know - qz.com
Ernexa Therapeutics Warrants (ERNAW) Hold at $0.05 as Price Action Remains FlatAccumulation Line - vinanet.vn
Ernexa Therapeutics (ERNA) Slips 2.2% to $4.17, Testing Key Support Amid Biotech PullbackCatalyst Driven Stocks - Vinanet
Ernexa Therapeutics (ERNA) Slips 0.7% to $4.27, Holds Above Key Support at $4.06Regression Channel - vinanet.vn
Ernexa Therapeutics Warrants (ERNAW) Surge 20% to $0.06 as Speculative Interest BuildsFibonacci Extension - vinanet.vn
Ernexa appoints David Polinsky to board ahead of IND filing By Investing.com - Investing.com Nigeria
Ernexa appoints David Polinsky to board ahead of IND filing - Investing.com
Ernexa Therapeutics Strengthens Board with Veteran Biotech - GlobeNewswire
Ernexa Therapeutics Inc expected to post a loss of $3.84 a shareEarnings Preview - TradingView
Ernexa Therapeutics (NASDAQ: ERNA) details $9.5M loss and cash strategy - Stock Titan
Tranche Update on Ernexa Therapeutics Inc.'s Equity Buyback Plan announced on November 25, 2024. - marketscreener.com
Price to sales forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Price to earnings forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Price to book forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Ernexa Therapeutics Inc. Revenue Breakdown – NASDAQ:ERNAW - TradingView
Ernexa Therapeutics Warrants (ERNAW) Hold Flat at $0.04 as Support and Resistance AlignCall Resistance - vinanet.vn
Ernexa Therapeutics (ERNA) Drops Nearly 5% as Bearish Pressure Builds Near Key SupportMarket Profile - dars.gov.et
Ernexa Therapeutics Inc. Revenue Breakdown – BOATS:ERNAW - TradingView
Ernexa Therapeutics (ERNA) Poised at Support: Is the Consolidation Nearing an End?Virgin POC - dars.gov.et
Ernexa Therapeutics Inc. (ERNA) stock price, news, quote and history - Yahoo Finance UK
Ernexa Therapeutics Inc. (ERNA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ernexa Therapeutics advances ERNA-101, a cell t... - Pluang
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 - GlobeNewswire
Tumors cleared in about two-thirds of animals in ERNA-101 study - Stock Titan
Ernexa Therapeutics Highlights ERNA-101 Combination-Therapy Potential, Preclinical Tumor Clearance Data and IND Progress - Quiver Quantitative
Ernexa's Innovative Approach to Cancer Treatment - Intellectia AI
Ernexa Therapeutics (ERNA) Plunges 10%: Key Support and Resistance Levels to WatchHidden Order - vinanet.vn
ERNA Q3 2023 Earnings: Loss Per Share Deepens, Stock Slides 16.39%Annual Earnings Summary - Vinanet
Ernexa Therapeutics Warrants (ERNAW) Hold Steady at $0.07: Minimal Price Action in Thin TradingRSI Overbought Alerts - vinanet.vn
Price to book forward of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy - Sahm
3 Most Active Penny Stocks to Watch Today, 7/16/2026 - TipRanks
ERNA Stock Whipsaws As Ernexa Maps Path To First Human Trial - StocksToTrade
ERNA stock jumps as investors appear to refocus on ERNA-101 clinical milestones - Quiver Quantitative
ERNA Stock Pops As Ernexa Flags Progress Toward First Trials - StocksToTrade
Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA) - Yahoo Finance
ERNA Stock Draws Trader Attention As Biotech Maps 2026–2027 Trial Roadmap - timothysykes.com
Wednesday's pre-market session: top gainers and losers - ChartMill
Ernexa's ERNA-101 combo clears tumors and boosts survival in ovarian cancer preclinical study. - Pluang
Ernexa reports positive preclinical data for cancer therapy By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Ernexa Therapeutics Reports Independent Preclinical Validation of ERNA-101 Combination Therapy Ahead of Planned IND Submission - Quiver Quantitative
Ernexa Therapeutics stock surges 30% on preclinical data By Investing.com - Investing.com Canada
Ernexa Therapeutics Receives Independent Validation of - GlobeNewswire
NeOnc, Ernexa, and VivoSim Announce Key Developments - Intellectia AI
Ernexa plans IND filing for ovarian cancer therapy ERNA-101 By Investing.com - Investing.com Canada
Ernexa Therapeutics plans first-in-human trial of ERNA-101 for ovarian cancer in late 2026 - Pluang
Preclinical ovarian models: Ernexa's ERNA-101 cleared tumors with PD-1 blockade - Stock Titan
Ernexa Therapeutics (ERNA) Rallies 3.3% as Biotech Sentiment ImprovesMESA MA - dars.gov.et
Ernexa Therapeutics Inc (ERNA) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):